CA-XSOLLA
17.7.2024 14:01:31 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the launch of Xsolla Instant Game Sales, Instant Launcher, and Instant Cloud Gaming following the release of Instant Web Shop in March 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717305685/en/
(Graphic: Xsolla)
We have listened to developers express their primary challenges—resource allocation is crucial, yet many struggle to quickly go live with their games and offerings. In response, our streamlined approach facilitates seamless integration and provides developers of any size with instant tools to open new revenue streams for their games. Xsolla partners with game developers and studios of all sizes, offering a swift process to sign license agreements, integrate solutions, and generate revenue promptly, accelerating go-to-market time with direct-to-consumer solutions.
David Stelzer, President of Xsolla, comments: "Xsolla Instant Solutions suite enables developers to quickly and easily launch new monetization channels for their games, attract new paying audiences, and boost revenue by leveraging Xsolla’s comprehensive suite of solutions. We aim to help developers unlock new revenue opportunities while reducing time to market to one day, similar to what we did with the Instant Web Shop launch earlier this year."
Instant Web Shop
Instant Web Shop enables game developers to swiftly set up a fully operational online store for their mobile games, seamlessly transforming a simple link into a revenue-generating platform. This solution increases awareness of the advantages of online purchases and facilitates an effortless shift to a robust LiveOps monetization system, enhancing user engagement and maximizing revenue streams. Instant Web Shop also helps game developers generate more value and purchases with personalization, limited-time offers, promotions, and deep linking.
For more information about Xsolla Instant Web Shop or to sign up, visit: xsolla.pro/ws1
Instant Game Sales
Instant Game Sales empowers developers to create store pages and initiate direct-to-consumer sales by importing content directly from Steam and Epic Game Store. This enables developers to integrate these offerings into their Game Sales page. It facilitates immediate game key sales during pre-orders and pre-launch phases, game releases, and seasonal promotions.
For more information about Xsolla Instant Game Sales or to sign up, visit: xsolla.pro/gs1
Instant Launcher
The Instant Launcher is receiving a significant update to enhance its content delivery system. Developers can import content directly from Steam and Epic Game Store to access a pre-designed launcher app with pre-created design, details, and assets to enable instant direct-to-consumer distribution of their games. Instant Launcher benefits games at any release stage, powering test flights during pre-launch, upcoming launch, and further game monetization. With Launcher, developers can easily directly engage with their audience while cross-promoting their games inside one gaming hub, decreasing the average cost per lead.
For more information about Xsolla Instant Launcher or to sign up, visit: xsolla.pro/launcher1
Instant Xsolla Cloud Gaming
Instant Cloud Gaming offers a self-serve solution for seamless game distribution by rapidly launching a branded cloud gaming platform in as little as 30 minutes to 24 hours. Xsolla Cloud Gaming enables developers to engage directly with their audience by offering pre-launch testing, sharing early versions of their games with the community, and providing the opportunity to demo the game directly from the landing page. Scaling game access to any device ensures quick access to new revenue streams and guarantees reaching more players globally.
For more information about Xsolla Instant Cloud Gaming or to sign up, visit: xsolla.pro/cg1
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240717305685/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom